Document:

<PAGE>

                                                                   EXHIBIT 10.22

February 4, 2000

Wendi V. Rodrigueza, Ph.D.
Esperion Therapeutics, Inc,
3621 South State St.
695 KMS Place
Ann Arbor, MI 48108

Tel.: (734) 332-0506 ext. 213
Fax-  (734) 332-0516

ESTH1000C:  Service Agreement Valid for Thirty days

                               Service Agreement

______________________________________________________________________________

   Formulation Transfer and Manufacturing of Phospholipid LUV for Injection
              for Aseptically Manufactured Toxlcological Supplies

Background:

Esperion Therapeutics, Inc. ("Esperion") has requested that AAI perform a review
of their formulation and manufacturing process for phospholipid large
unilamellar vesicles (LUV) for injection.  Upon completion of the review, AAI
will prepare aseptically manufactured toxicological supplies.  AAI will deliver
to Esperion specifications for the product and the raw materials, development
reports (including weekly summaries), technical transfer document, manufacturing
support, product, batch records.  Per the attached timeline, AAI estimates
delivery of the aseptically manufactured supplies 8 weeks after execution of the
contract and receipt of materials, methods and equipment.

Revision History:

Revision C   Changes document to a Service Agreement, corrects typographical
             error in terms section, provides table of activities and costs to
             the terms section based on a go/no go decision after review of
             particle size and sterility data from the lab scale up batch
             (section II.B.), adds milestone payment schedule.

Revision B   Incorporates changes requested by Esperion in e-mail from Esperion
             on January 24 and 25 and additional environmental monitoring and
             clarification of text requested by AAI.

Revision A   Includes changes requested by Esperion in e-mail dated 1/19/2000
             and additions following review by Dr. Toney-Parker.
<PAGE>

ESTH1000C
February 4, 2000
Page 2

Proposal:

AAI proposes to perform the following activities:

I.   Definition

     A.  AAI WILL REVIEW PERTINENT INFORMATION SUPPLIED BY ESPERION SUCH AS
         PREFORMULATION, FORMULATION AND METHOD OF MANUFACTURE.

     B.  ESPERION WILL PROVIDE PHOSPHOLIPID MATERIAL ALONG WITH MSDS AND
         CERTIFICATE OF ANALYSIS.

     C.  ESPERION WILL PROVIDE TO AAJ, FOR USE IN THE ACTIVITIES OUTLINED BELOW,
         AN AVESTIN EXTRUDER. AAI WILL ORDER ALL SPARE PARTS AND ASSOCIATED
         COSTS WILL BE PASSED THROUGH TO ESPERION. THE EXTRUDER AND ALL SPARE
         PARTS WILL BE RETURNED TO ESPERION UPON COMPLETION OF THE PROJECT OR
         UPON ESPERION'S REQUEST.

     D.  ESPERION WILL PROVIDE A NICOMP FOR PARTICLE SIZE ANALYSIS. AAL WILL
         ORDER ALL SPARE PARTS AND ASSOCIATED COSTS WILL BE PAID THROUGH TO
         ESPERION. THE NICOMP AND ALL SPARE PARTS WILL BE PASSED THROUGH TO
         ESPERION UPON COMPLETION OF THE PROJECT OR UPON ESPERIONS REQUEST.

     E.  AAI WILL SOURCE OTHER MATERIALS REQUIRED TO PERFORM THE ACTIVITIES
         OUTLINED HEREIN.

     F.  AAI WILL SOURCE PACKAGE COMPONENTS TAKING IN TO CONSIDERATION WHAT HAS
         BEEN PREVIOUSLY VALIDATED AT THE TRANSFER SITE FOR THE GMP SUPPLIES AND
         WHAT IS CURRENTLY USED IN PHOSPHOLIPID PRODUCTS CURRENTLY ON THE
         MARKET.

Estimated Cost (Section I.)..........................................  No Charge

II.  Formula Transfer

     A.  AAI WILL PREPARE UP TO 3 BATCHES OF THE PHOSPHOLIPID LUV FORMULATION
         BASED ON THE FORMULA AND METHOD OF MANUFACTURE PROVIDED BY ESPERION.
         EMPHASIS WILL BE ON FORMULA AND PROCESS OPTIMIZATION REQUIRED FOR
         TRANSFER TO A GMP MANUFACTURING SITE. SEVERAL BATCHES WILL BE RUN TO
         DETERMINE AND OPTIMIZE PROCESS PARAMETERS REQUIRED ACHIEVING A LUV
         PARTICLE SIZE DISTRIBUTION OF 80 - 140 NM (DIAMETER). PREPARATION OF
         THE BATCH WILL INCLUDE
<PAGE>

ESTH1000C
February 4, 2000
Page 3

           EVALUATION OF 2 VENDORS OF THE MILLIPORE PORETICS MEMBRANES, SEVERAL
           PORE SIZES, STACKED, ETC. AAI WILL SELECT THE OPTIMAL MEMBRANE(S) TO
           OBTAIN A PARTICLE SIZE X\\90\\ = 100 - 130 NM. THE BATCH WILL BE
           OVERLAYED WITH ARGON. TESTING OF THIS BATCH WILL INCLUDE:

           1.  APPEARANCE
           2.  ETLC FOR POPC
           3.  VISCOSITY
           4.  PH
           5.  PARTICLE SIZE BY NICOMP
           6.  OSMOLARITY
           7.  CONCENTRATION

       B.  LABORATORY SCALE-UP BATCH MANUFACTURE

           AAI will manufacture a laboratory scale-up batch to establish
           processing and parameters, and specifications for in process and
           finished product testing. This batch will be conducted as a trial
           batch for the batches to be used in Esperion's toxicology studies.
           Flow decay/bubble point will be conducted as a part of this batch or
           as a part of the batches prepared in section II.A.

           The following tests will be conducted on this batch:

           1.  APPEARANCE
           2.  HPLC FOR POPC
           3.  LHP
           4.  LAL
           5.  FILL VOLUME
           6.  VISCOSITY
           7.  PH
           8.  PARTICLE SIZE
           9.  PARTICULAR MATTER (MICROSCOPIC LIGHT OBSTRUCTION OR VISUAL)
           10. STERILITY

Note:  AAI will review all data, including 14 day sterility data, prior to
       beginning activities described in section VLD.

       C.  ENVIRONMENTAL MONITORING FOR VIABLE PARTICULATES

           AAI will perform one (1) evaluation for viable (RCS) and -non viable
           particulates in the environment before manufacturing in the clean
           environment, and perform 1 - 2 evaluations for viable particulates
           (settling plates and RCS) during processing
<PAGE>

ESTH1000C
February 4, 2000
Page 4

           (2 to 3 total) of the laboratory scale batch. AAI will also verify
           sterility of the argon gas.

       D.  ACCELERATED STABILITY PROGRAM - THE BATCH IN SECTION II.B. WILL BE
           PLACED ON A SHORT-TERM ACCELERATED STABILITY PROGRAM, WITH TWO
           CONTAINER ORIENTATIONS -UPRIGHT AND INVERTED:

                 Condition                Timepoint
                 25(degree)C/60%RH        Initial, 0.5 1, 2 and 3 months
                 40(degree)C/75%RH        0.5, 1, 2, and 3 months
                 30(degree)C/60%RH        Test only if a problem arises at
                                          40(degree)C/75%RH
                 5(degree)                Control

Note:  If testing of the 5(degree) or 30(degree)C/60%RH is deemed necessary, it
       will be covered under a separate document.

           The following tests may be conducted at each timepoint:

           1.  BPLC FOR POPC
           2.  LHP
           3.  PARTICLE SIZE
           4.  APPEARANCE
           5.  PH
           6.  VISCOSITY
           7.  PARTICULATE MATTER (MICROSCOPIC LIGHT OBSTRUCTION OR VISUAL)

     E.    MATERIAL CONTRACT STUDIES

           These studies will be outlined and conducted under the most recent
           signed revision of ESTH1003. In addition, Esperion has stated that
           the material should be filtered using a polyethersulfone filter, that
           the stopper used should be the same (if possible) as used for
           Intralipid and that vials should be those validated by the
           manufacturer that will be used for the GMP batches described in
           ESTH1001.

     F.    OXYGEN SENSITIVITY STUDY

           These studies will be outlined and conducted under the most recent
           signed revision of ESTH1003.

     G.    REPORT PREPARATION

           1.  AAI WILL PROVIDE WEEKLY SUMMARIES, IN THE FORM OF MEETING
               MINUTES, FOLLOWING CONFERENCE CALLS.
<PAGE>

ESTH1000C
February 4, 2000
Page 5

           2.  AAI WILL PREPARE A SUMMARY REPORT OF THE RESULTS AND STUDIES
               CONDUCTED HEREIN. A SUMMARY REPORT CONSISTS OF A SUMMARY, IN
               TABULAR FORMAT WITH A SUCCINCT DISCUSSION OF THE EXPERIMENTAL AND
               RESULTS. IF REQUESTED, AAI CAN SUPPLY A DETAILED SCIENTIFIC
               REPORT OF STUDIES CONDUCTED. ACTIVITIES TOWARDS THE PREPARATION
               OF A SCIENTIFIC REPORT WILL BE CONDUCTED IN A SEPARATE DOCUMENT.

Estimated Cost (Section II.)...........................................  $87,100

III. ANALYTICAL SUPPORT OF THE PRODUCT

       A.  AAI WILL PROVIDE FULL RELEASE TESTING OF THE BULK PHOSPHOLIPID PER
           SPECIFICATIONS PROVIDED BY ESPERION.

Note:  Should method development work be required for the use of any of the
       methods required for release of the phospholipid, a description of
       activities and associated costs will be covered under a separate
       document.

       B.  ESPERION WILL TRANSFER THE FOLLOWING METHODS TO AAL PROTOCOLS WILL BE
           GENERATED AND APPROVED BY ESPERION PRIOR TO TRANSFER OF EACH METHOD.
           TRANSFER WILL CONSIST OF FIVE SAMPLE PREPARATIONS FROM A SINGLE AMPLE
           AND ONE ANALYST ON THE SAME DAY.

           1.  IPLC FOR POPC
           2.  SPERTOPHOTOMETRIC FOR LIPID HYDROPEROXIDE ("LHP")

Note:  Transfer and validation of the HPLC analytical methods is based on
       looking at different classes of phospholipids, not fatty acids. AAI will
       use HPLC with ELSD and is based on the method analyzing one or two
       phospholipids. In addition, AAI will reevaluate testing prices upon
       completion of the method transfers.

       C.  AAI WILL DEVELOP/VALIDATE THE FOLLOWING MICROBIOLOGICAL METHODS:

           1.  LAL
           2.  STERILITY VALIDATION

       D.  ANALYTICAL METHOD VALIDATION

           1.  AAI WILL PERFORM LIMITED VALIDATION (LINEARITY, ACCURACY,
               RECOVERY AND PRECISION) IN SUPPORT OF THE HPLC FOR POPC METHOD.
<PAGE>

ESTH1000C
February 4, 2000
Page 6

          2.  AAI WILL PERFORM LIMITED VALIDATION (LINEARITY, ACCURACY, RECOVERY
              AND PRECISION) IN SUPPORT OF THE SPECTROPHOTOMETRIC ASSAY FOR
              LIPID HYDROPEROXIDE.

     E.   CLEANING VERIFICATION SUPPORT

          At this than AAI anticipates the use of dedicated equipment and hand
          filling of the aseptically manufactured toxicological supplies.  Based
          on this, the need for analytical methodology for a direct sampling
          technique for use in a cleaning validation program is not required.

     F.   RELEASE OF PACKAGE COMPONENTS

          AAL will fully release test all package components required for the
          project as described including those required for the fill of the
          toxicology supplies.  Esperion will provide AAI with label copy for
          the toxicology supplies.

Estimated Cost (Section III.A - F.)..................................... $46,635

     G.   RELEASE TESTING OF THE PRODUCT - 4 LOTS:

          1.  APPEARANCE
          2.  HPLC FOR POPC
          3.  LHP
          4.  LAL
          5.  FILL VOLUME
          6.  VISCOSITY
          7.  PH
          8.  PARTICLE SIZE
          9.  PARTICULAR MATTER (MICROSCOPIC LIGHT OBSTRUCTION OR VISUAL)
          10. STERILITY

Estimated Cost (Section III.G).......................................... $16,980

IV.  PROJECT MANAGEMENT

     The project team will consist of a team leader from AAI's Formulation
     Development Laboratory (FDL), and appropriate representatives from other
     disciplines involved in project execution.

     A.   AAI WILL PROVIDE A MANAGEMENT TEAM TO COMMUNICATE PROJECT PROGRESS AND
          REVIEW ALL WORK FOR SCIENTIFIC INTEGRITY ACCORDING TO TIMELINES
          MUTUALLY AGREED UPON BY AAI AND ESPERION.
<PAGE>

ESTH1000C
February 4, 2000
Page 7

     B.   TELECONFERENCES WILL BE HELD, AT REGULAR INTERVALS, BETWEEN THE
          PARTIES THAT ESPERION IDENTIFIES AND AAI.

V.   CONSULATIVE PROJECT MANAGEMENT

     AAI will provide on with a technical contact person for  project
     discussions and consultation in addition to up to six hours of weekly
     conference calls.  The time spent consulting with Esperion and providing
     technical support (including regulatory support) will be invoiced to
     Esperion at $165/hour.  AAI estimates that this additional consultative
     support may range from 2 to 4 hours per week.

Estimated Cost (Section V.)............................................ As Used

VI.  ASEPTICALLY MANUFACTURED TOXICOLOGICAL SUPPLIES

     A.   PRODUCT TRANSFER

          Activities that may be included as part of product technology transfer
          are:

          1.  PREPARATION OF A MASTER BATCH RECORD
          2.  RAW MATERIAL, IN-PROCESS AND FINAL PRODUCT SPECIFICATIONS
          3.  BATCH RECORD REVIEW AND SIGN-OFF BY AAI AND ESPERION

     B.   RAW MATERIALS

          AAI will release test all raw materials for use in the preparation of
          the aseptically manufactured toxicological supplies.

     C.   ENVIRONMENTAL MONITORING FOR VIABLE PARTICULATES

          AAI will perform one (1) evaluation for viable (RCS) and non viable
          particulates in the environment before manufacturing in the clean
          environment, and perform 1 -2 evaluations for viable particulates
          (settling plates and RCS) during processing.  (2 to 3 total).

     D.   MANUFACTURE OF LUV FOR INJECTION WITH THE FOLLOWING ASSUMPTIONS:

          Manufacture of up to four lots of 25 -L batch size to provide 4 kg of
          material following samples being removed for release testing, retains
          and stability.  Sampling of package components during manufacture to
          be used as controls.  Filling of finished product into 50ml glass
          bottles

          Labeling for both stability and toxicology studies
<PAGE>

ESTH1000C
February 4, 2000
Page 8

Estimated Cost (Section VI.)...........................................  $47,900

Note:  The aseptic fill process has not validated.

VII.   Storage and Testing of the Aseptically Manufactured Toxicology Supplies

       AAI will piece one of the four aseptically manufactured batches on the
       following accelerated stability program. Materials will be set in both
       the upright and inverted configurations, only one configuration will be
       tested.

          Condition                  Timepoint
          23(degree)C/60%*RH         Initial, 3, 6, 9, 12, 18, 24 and 36 months
          40(degree)C/750%           1, 3 and 6 months
          30(degree)C/60%RH          Test only if a problem arises at
                                     40(degree)C/75%RH
          5(degree)C                 Control

Note:  If testing of the 5(degree)C or 30(degree)C/60%RH is deemed necessary, it
       will be covered under a separate document.

       The following tests will be conducted at each timepoint:

       A.  HPLC for POPC
       B.  LHP
       C.  Particle size
       D.  Appearance
       E.  Viscosity
       F.  Particulate matter (microscopic light obstruction or visual)
       G.  LAL (6 months at 40(degree)C/75%RH and 12, 24 and 36 months at
           25(degree)C/60%RH)
       H.  Sterility (6 months at 40(degree)/75%RH and 12, 24 and 36 months at
           25(degree)C/60%RH)

Note:  Esperion may elect to not conduct a stability study on the aseptically
       manufactured batch. If Experion elects not to conduct this stability
       study, there will be no charges for activities not conducted.

       Estimated Cost (Section VII.)................................... $39,015

VIII.  Regulatory Support

       Esperion may elect to utilize AAI's regulatory affairs group during the
       development of their product. Should Esperion elect to do so, AAI's
       regulatory consulting services will be charged at a rate of $165 per
       hour. Services would not be conducted without prior authorization from
       Esperion.

Estimated Cost (Section VIII.).............................Hourly, if requested
<PAGE>

ESTH1000C
February 4, 2000
Page 9

Terms and Conditions:

     At this time, it is estimated that all activities outlined above will cost
$237,720.  Should Esperion elect to terminate the program following completion
of testing of the lab scale up batch described in section II.B. the following
schedule describes activities and costs that will have been completed by that
date.

                          Early Termination Schedule
for decision to terminate the project following receipt of results from Section
                                     II.B.

<TABLE>
<CAPTION>
----------------------------------------------------------------------------------------------------------
Service Estimate              Description              Completion date          Estimated Cost
Section                                                (assumes 2/8/00
                                                       signature date)
----------------------------------------------------------------------------------------------------------
<S>                           <C>                      <C>                      <C>
I                             Project Definition       February 11, 2000        No Charge
----------------------------------------------------------------------------------------------------------
II.A., B., C., G.1.           Formula Transfer         March 22, 2000           $51,155
(thru termination)            including testing in
                              section II.B.
----------------------------------------------------------------------------------------------------------
III.A., B., C., D., F.        Analytical Support       March 24, 2000           $46,635
----------------------------------------------------------------------------------------------------------
V.                            Consultative Project     N/A                      As described, if used
                              Management
----------------------------------------------------------------------------------------------------------
</TABLE>

Based on a decision to proceed:

<TABLE>
<CAPTION>
----------------------------------------------------------------------------------------------------
Service Estimate        Description                   Completion date          Estimated Cost
 Section                                              (assumes 2/8/00
                                                      signature date)
----------------------------------------------------------------------------------------------------
<S>                     <C>                           <C>                      <C>
II.D., G.1., G.2.       Stability, weekly and         June 5, 2000             $35,945
                        final report
----------------------------------------------------------------------------------------------------
III.G.                  Release of up to 4 lots       April 24, 2000           $16,980
----------------------------------------------------------------------------------------------------
V.                      Consultative Project          N/A                      As described, if used
                        Management
----------------------------------------------------------------------------------------------------
VI.                     Aseptically                   April 25, 2000           $47,990
                        manufactured Supplies
----------------------------------------------------------------------------------------------------
VII.                    Stability                     April 28, 2003           $39,015
----------------------------------------------------------------------------------------------------
</TABLE>

The project will be initiated upon Esperion acceptance of this proposal,
assignment of a purchase order number, and prepayment in the amount of $32, 500.
Prepayments shall be credited against the first two invoices until the
prepayment is exhausted Unless otherwise agreed, according to the following
milestone schedule:
<PAGE>

ESTH1000C
February 4, 2000
Page 10

                              Milestone Schedule

<TABLE>
<CAPTION>
-----------------------------------------------------------------------------------------------------------
Milestone               Deliverable                           Estimated Invoice Date      Milestone Payment
-----------------------------------------------------------------------------------------------------------
<S>                     <C>                                   <C>                         <C>
1                       Up front payment                      With signature              $32,600
-----------------------------------------------------------------------------------------------------------
2                       Test report for laboratory scale      April 1, 2000               $34,855
                        batch as described in section II.B.
----------------------------------------------------------------------------------------------------------
3                       Method Validation reports, test       April 1, 2000               $30,335
                        reports
----------------------------------------------------------------------------------------------------------
</TABLE>

Remaining schedule with decision to proceed:

<TABLE>
<CAPTION>
--------------------------------------------------------------------------------------------------
Milestone   Deliverable                           Estimated Invoice Date         Milestone Payment
--------------------------------------------------------------------------------------------------
<C>         <S>                                   <C>                            <C>
4           Up front payment                      With decision to proceed       $ 33,600
--------------------------------------------------------------------------------------------------
5           Stability data and final summary      Upon delivery of final         $ 24,745
            report                                report
--------------------------------------------------------------------------------------------------
6           Release test report (CofA's for 4     May 1, 2000                    $  5,780
            batches)
--------------------------------------------------------------------------------------------------
7           Aseptic batches submitted for final   April 5, 2000                  $ 36,790
            testing
--------------------------------------------------------------------------------------------------
8           Initiation of stability, 1 month      Upon completion of testing     $ 10,945
            pull
--------------------------------------------------------------------------------------------------
9           Following each stability pull -       Upon completion of testing     $4,010 per pull
            delivery of data
--------------------------------------------------------------------------------------------------
                                                                                 $237,720
---------------------------------------------------------------------------------------------------
</TABLE>

     This cost estimate is based on the information available and AAIs
experience with the procedures involved. AM reserves the right to review this
estimate should the scope of the project change or should unforeseen
difficulties arise.  Any changes in the scope or the nature of the work covered
by this Service Agreement must be mutually agreed to and confirmed by a written
"Change Order".

     In addition, Esperion will be charged for all out-of-pocket costs and/or
expenses associated with the activities outlined herein. Such costs and expenses
shall include required materials, travel and shipping expenses, and lab supplies
such as columns, standards and chemicals unavailable from Esperion.  AAI shall
notify Esperion prior to incurring any unusual cost or expense exceeding $1,500.

     Stability setup and storage charges are due i id payable upon Initiation of
the study. Any revisions to the stability protocol made after the initiation of
the stability study will be billed at $125 per hour for changing the protocol.

     Esperion shall be entitled to terminate the project at any time on thirty
(30) days' prior written notice. In the event of cancellation, Esperion will be
obligated to pay only the cost of work, materials and services (exclusive of
stability setup and storage charges) used for the
<PAGE>

February 4, 2000
Page 11

project through the effective date of the cancellation, as well as AAI's cost of
all materials and services previously acquired or contracted for and which
cannot be utilized in other day-to-day

AA1 Proprietary Technology:

     Esperion recognizes that in conducting the feasibility study described in
this Service Agreement, AM may utilize fonnulation technology that is
proprietary to AAI ("AAI Proprietary Technology"). Notwithstanding anything
contained herein to the contrary, Esperion shall own all inventions,
discoveries, improvements on data (collectively, "Inventions") reduced to
practice by AAI or Esperion in connection with this Service Agreement, including
data resulting from AAI conducting such feasibility study. AAI shall fully
cooperate with Esperion in obtaining, at Esperion's sole costs and expense, any
patent and/or other protection as may be available with respect to such
Inventions and shall execute all documents deemed reasonably necessary by
Esperion for purposes of procuring such patent and/or other protection. AAI
agrees that it shall contractually ensure the prompt disclosure to Esperion by
any employee of any Inventions arising hereunder, as well as their cooperation
in securing patent and/or other protection as set forth herein. No right, title
or interest to any such AAI Proprietary Technology is granted to Esperion under
this Service Agreement except as otherwise provided herein. For the avoidance of
doubt, the Inventions shall not be deemed AAI Proprietary Information. In the
event Esperion chooses to further develop and/or commercialize a formulation
comprising, in part or in whole, AAI Proprietary Technology, Esperion will
obtain a license from AAI to use such AAI Proprietary Technology, in thc form of
a license agreement, such agreement which shall be memorialized in a separate
writing and negotiated in good faith by AAI and Esperion. Such agreement should
provide the right to Esperion to make, use, sell, and import a pharmaceutical
product using AAI Proprietary Technology with a right to sublicense, in a
territory, and with financial terms, to be mutually agreed upon, but AAI shall
retain all right, title, and interest to any and all United States and/or
international patent applications and/or issued patents claiming such AAI
Proprietary Technology.

Indemnification:

     Esperion shall indemnify and hold AAI and AAI's affiliates harmless against
any claims asserted or suits brought against AAI or AAIs affiliates arising out
of; or connected with, materials provided to AAI by Esperion except where such
claim or suit is a direct result of AAI or AAI's affiliates gross negligence in
the performance of any obligation imposed hereunder. Provided, however, that AAI
or AAI's affiliates will promptly notify Esperion of any such claim or suit, and
at Esperion's discretion and cost, permit Esperion's attorneys to handle and
control such claims or suits exclusively so long as Esperion's attorneys
actively pursue the defense of the same.

     AAI shall indemnify and hold Esperion and Esperion's affiliates harmless
against any claims asserted or suits brought against Esperion or Esperion's
affiliates arising out of, or connected with the gross negligence of AAI in the
performance of any obligation imposed hereunder. Provided, however, that
Esperion or Esperion's affiliates will promptly notify AAI of any such claim or
suit, and at AAI's discretion and cost, permit AAI's attorneys to handle arid
<PAGE>

February 4, 2000
Page 12

control such claims or suits exclusively so long as AAI's attorneys actively
pursue the defense of the same.

     In no event shall either party be liable to the other for any special,
indirect or consequential damages, including lost profit.

Nondisclosure:

     AAI agrees that it will not itself use, or provide to, disclose to, or
permit any third party to use any Esperion Confidential Information (as defined
below). Except as otherwise provided herein, AAI shall retain all right, title
and interest to its proprietary trade secrets, know-how, inventions, whether
patentable or not, and other intellectual property ("AAI Technology"). All
Esperion Confidential Information will be maintained in secrecy by AAI, and AAI
will use all reasonable diligence to prevent use or disclosure of any such
information for a period of five (5) years from the date hereof. This obligation
of confidentiality will survive termination of this estimate. As used herein,
"Esperion Confidential Information" means any and all trade secrets and
proprietary information (in any and every form and media) of Esperion or any of
its Affiliates, including, without limitation, (a) information, data, documents,
or other items which were developed or generated by AAI pursuant to this
Agreement, (b) information relating to existing or contemplated products,
services, technology, designs, processes, formulae, research and development (in
any and all stages) of Esperion or any of its Affiliates, and (c) information
relating to business plans, methods of doing business, sales or marketing
methods, customer lists, customer usage's and/or requirements and supplier
information of Esperion or any of its Affiliates. As used herein, "Affiliate"
means any person or entity that directly, or indirectly through one or more
intermediaries, controls or is controlled by or is under common control with
Esperion.

Excluded Materials:

     Notwithstanding the nondisclosure section set forth above, information,
data, or documents developed or generated by AAI solely for its internal use or
for persons other than Esperion is not restricted by the ownership rights to be
transferred to Esperion herein.

Compliance with Laws:

     AAI hereby covenants and agrees to perform all of its obligations pursuant
hereto in compliance with (a) all applicable laws, rules and regulations,
including standards of Good Manufacturing Practices, (b) all standards and
practice generally accepted in the industry, and (c) protocols provided by
Esperion to AAI from time to time.

Return of Material:

     Upon termination of this Agreement by Esperion (which termination may be
effected by Esperion upon thirty days written notice at AAI), AA shall return to
Esperion all Esperion Confidential Information and all other property provided
by Esperion to AAI pursuant hereto.
<PAGE>

February 4, 2000
Page 13

Insurance:

     AAI agrees to maintain and name Esperion as an additional insured under
such insurance policies and in such amounts as Esperion shall reasonably request
from time to time.

FDA Inspection:

     In the event that AAI receives a Notice of Inspection (hereinafter
"Notice") from the U.S. Food and Drug Administration (the "FDA") which relates
in any way to this Service Agreement, AAI shall (a) promptly notify Esperion in
writing of the Notice, (b) keep Esperion informed of the progress of the
inspection, and (c) provide a copy to Esperion of any documents produced to the
FDA pursuant to the Notice.

Announcements:

     No announcement, oral presentation or publication relating to any matter
described herein shall be made without the prior written approval of Esperion,
which approval may be granted or withheld by Esperion in its discretion.

Non Debarment:

     AAI warrants and represents that AAI has never been and is not currently
(a) debarred by the FDA, or an employer, partner, shareholder, member,
subsidiary or affiliate of any person or entity debarred by the FDA, from
providing services in any capacity to a person or entity that has an approved or
pending drug product application; or (b) a person or entity that has been
debarred by the FDA from submitting or assisting in the submission of an
abbreviated new drug application (a Debarred Entity") or an employer, partner,
shareholder, member, subsidiary or affiliate of a Debarred Entity.

     AAI further represents and warrants to Esperion that AAI has no knowledge
of any circumstances which may affect the accuracy of foregoing representations
and warranties, including, but not limited to, FDA investigations of, or
debarment proceedings against, AAI or any person or entity performing services
or rendering assistance relating to activities taken pursuant hereto.

Reports:

     AAI shall provide Esperion with weekly written reports describing with
specificity AAI's performance of its obligations hereunder.

Entire Agreement:

     This Service Agreement constitutes the entire agreement between Esperion
and AAI and shall supersede all previous communications, representations,
agreements or understandings, whether oral or written, between Esperion and AAI
with respect to the subject matter hereof.
<PAGE>

February 4, 2000
Page 14

Assignment:

     This Service Agreement shall not be assigned (whether by sale, stock
transfer, merger or otherwise) by either party without the prior written consent
of the other party. Notwithstanding anything herein to the contrary, in the
event Esperion merges with another entity, is acquired by another entity, or
sells all or substantially all of its assets to another entity, Esperion may
assign its rights and ob1i~ations hereunder to, in the event of a merger or
acquisition, the surviving entity, and in the event of a sale, the acquiring
entity, without AAI's consent so long as: (a) Esperion is not then in material
breach of this Agreement; and (b) AAI receives from the proposed assignee, in
writing, (i) reaffirmation of the terms of this Agreement; (ii) an agreement to
be bound by the terms of this agreement; and (iii) an agreement to perform the
obligations of Esperion under this Agreement.
<PAGE>

February 4, 2000
Page 15

                             AGREED AND ACCEPTED:

AIA:                                      ESPERION

/s/ Lizbeth B. Sherman                    /s/ Roger S. Newton
------------------------------------      -------------------------------------
Lizbeth B. Sherman                        Signature
Manager, Technical Marketing Group

         2-8-00                           President/CEO
------------------------------------      -------------------------------------
Date                                      Title

/s/ David A. Straight                                   2/8/00
------------------------------------      -------------------------------------
David Straight                            Date
Global Contracts Director

          2/8/00
------------------------------------      -------------------------------------
Date                                      Purchase Order Number

            For questions concerning this document, please contact:
                          Lizbeth B. Sherman, Manager
                           Technical Marketing Group
                                      AAI
                           1206 North 23/rd/ Street
                             Wilmington, NC 28405
                             Phone (910) 254-7247
                              Fax (910) 815-2300
<PAGE>

March 31, 2000

Wendi V. Rodrigueza, Ph.D.
Esperion Therapeutics, Inc.
3621 South State St.
695 KMS Place
Ann Arbor, MI 48108

Tel.:  (734) 332-0506 ext. 213
Fax:   (734) 332-0516

ESTH1000C.lb

                                 Change Order

________________________________________________________________________________

    Formulation Transfer and Manufacturing of Phospholipid for Aseptically
                    Manufactured Supplies Changes to Scope

Background:

     Esperion Therapeutics, Inc. ("Esperion") has requested that AAI perform a
review of their formulation and manufacturing process for phospholipid large
unilamellar vesicles (LUV) for injection.  Upon completion of the review, AAI
will prepare aseptically manufactured toxicological supplies.  AAI will deliver
to Esperion specifications for the product and the raw materials, development
reports (including weekly summaries), technical transfer document, manufacturing
support, product, batch records.  This document includes additional activities
either completed, in progress or planned based on the information and process
provided by Esperion.

Revision History:

Revision b   Removes LAL testing of 3 lots of material supplied by Esperion,
             redistributes milestone payments.

Revision a   Includes clarification of activities and associated costs.
<PAGE>

March 31, 2000
Page 2

Changes in Scope by Service Estimate Section:

<TABLE>
<CAPTION>
------------------------------------------------------------------------------------------------
 Activities:                                                 Section Changed:     Estimated Cost
------------------------------------------------------------------------------------------------
<S>                                                          <C>                  <C>
 7 TOC samples of the pressure vessels                       II.                  $     455
------------------------------------------------------------------------------------------------
 Media run of the aseptic fill process including sterility   II.                  $   5,300
 testing of the media
------------------------------------------------------------------------------------------------
 Hydration evaluation at RT and 37(degrees)C evaluation of   II.A.                $  14,790
 up front homogenization, filter evaluation, flow decay
 conducted at 3 pressures using a 0.22 filter, flow decay
 conducted at 3 pressures using a 0.45 and 0.22 filter
 stacked, bubble point on the argon gas, LHP testing and
 fill volume.  Testing not conducted includes HPLC for
 POPC.
------------------------------------------------------------------------------------------------
 Additions to testing on scale up batch include:             II.B.                $   4,150
 concentration (3), TLC, osmolality, headspace GC, MLT
 (2).  Deletions to testing include: RPLC for POPC and
 viscosity.
------------------------------------------------------------------------------------------------
 3 month scale up batch stability                            II.D.                 ($21,305)
------------------------------------------------------------------------------------------------
 Identification, LAL and appearance of three lots of POPC    III.A.               $   5,735
 API, including LAL validation of API
------------------------------------------------------------------------------------------------
 Full release of one lot of POPC API                         III.A.                 ($3,800)
------------------------------------------------------------------------------------------------
 TLC identification method transfer, including translation   III.B.               $   3,500
 of the method provided by Esperion
------------------------------------------------------------------------------------------------
 Transfer of the concentration method                        III.B.               $   2,500
------------------------------------------------------------------------------------------------
 Transfer of HPLC for POPC method                            III.B.                 ($2,000)
------------------------------------------------------------------------------------------------
 Partial validation of the TLC identification test           III.D.               $  10,000
------------------------------------------------------------------------------------------------
 Partial validation of the concentration test                III.D.               $  10,000
------------------------------------------------------------------------------------------------
 Partial validation of the HPLC for POPC method              ffl.D.                ($16,800)
------------------------------------------------------------------------------------------------
 Additions to release testing include: concentration, TLC,   III.G.               $   2,540
 osmolality, headspace GC, deletions include HPLC for
 POPC, viscosity.
------------------------------------------------------------------------------------------------
 Charges associated with increased batch size (double) for   VI.D.                $  27,400
 the aseptically manufactured batches.
------------------------------------------------------------------------------------------------
 Changes to stability of aseptically manufactured            VII.                   ($1,180)
 supplies, per protocol approved by Esperion
------------------------------------------------------------------------------------------------
                                                                                  $  40,655
------------------------------------------------------------------------------------------------
</TABLE>

Terms and Conditions:

     The additional cost for the activities described above are $40,655 plus
$120/organism identification conducted by microbiology.

     Unless otherwise agreed, AAI will invoice Esperion according to the
following milestone schedule:
<PAGE>

March 31, 2000
Page 3

                              Milestone Schedule

<TABLE>
<CAPTION>
 Milestone  Deliverable                      Estimated Invoice Date           Milestone Payment
--------------------------------------------------------------------------------------------------
<S>         <C>                              <C>                              <C>
    1       Up front payment                 With signature                   $  32,600
--------------------------------------------------------------------------------------------------
    2       Test report for laboratory       April 17, 2000                   $  40,655
            scale batch as described in
            section II.B.
--------------------------------------------------------------------------------------------------
    3       Method validation reports        June 1, 2000.                    $  34,765
--------------------------------------------------------------------------------------------------
    4       Batch record                     April 10, 2000                   $   8,815
--------------------------------------------------------------------------------------------------
    5       Release test report (CofA's      May 8, 2000                      $  50,975
            for 4 batches)
--------------------------------------------------------------------------------------------------
    6       Aseptic batches submitted for    April 17, 2000                   $  67,360
            final testing
--------------------------------------------------------------------------------------------------
    7       Initiation of stability, 1       Upon completion of testing       $  22,486
            month pull
--------------------------------------------------------------------------------------------------
    8       Following each stability pull    Upon completion of testing per   $4,143.80 per pull
            -- delivery of data              stability pull                   (5 pulls)
--------------------------------------------------------------------------------------------------
                                                                              $ 278,375
--------------------------------------------------------------------------------------------------
</TABLE>

     This cost estimate is based on the information available and AAI's
experience with the procedures involved.  AAI reserves the right to revise this
estimate should the scope of the project change or should unforeseen
difficulties arise.  Any changes in the scope or the nature of the work covered
by this Service Agreement must be mutually agreed to and confirmed by a written
"Change Order".

     In addition, Esperion will be charged for all out-of-pocket costs and/or
expenses associated with the activities outlined herein.  Such costs and
expenses shall include required materials, travel and shipping expenses, and lab
supplies such as columns, standards and chemicals unavailable from Esperion.
AAI shall notify Esperion prior to incurring any unusual cost or expense
exceeding $1,500.

     Stability setup and storage charges are due and payable upon initiation of
the study.  Any revisions to the stability protocol made after the initiation of
the stability study will be billed at $125 per hour for changing the protocol.

     Esperion shall be entitled to terminate the project at any time on thirty
(30) days' prior written notice.  In the event of cancellation, Esperion will be
obligated to pay only the cost of work, materials and services (exclusive of
stability setup and storage charges) used for the project through the effective
date of the cancellation, as well as AAI's cost of all materials and services
previously acquired or contracted for and which cannot be utilized in other day-
to-day operations.

     All activities will be conducted as described in the terms and conditions
in ESTH1000C.
<PAGE>

March 31, 2000
Page 4

                             AGREED AND ACCEPTED:

AIA:                                   ESPERION

/s/ Lizbeth B. Sherman                 /s/ Roger S. Newton
----------------------------------     ------------------------------------
Lizbeth B. Sherman                     Signature
Manager, Technical Marketing Group

        3-31-00                        President/CEO
----------------------------------     ------------------------------------
Date                                   Title

/s/ Ashley De Stefano                      March 31, 2000
----------------------------------     ------------------------------------
Ashley De Stefano                      Date
Global Contracts Director

          3-31-00
----------------------------------     ------------------------------------
Date                                   Purchase Order Number

            For questions concerning this document, please contact:
                          Lizbeth B. Sherman, Manager
                           Technical Marketing Group
                                      AAI
                           1206 North 23/rd/ Street
                             Wilmington, NC 28405
                             Phone (910) 254-7247
                              Fax (910) 815-2300<PAGE>

                                                                   Exhibit 10.23

          FORM OF RESTRICTED STOCK PURCHASE AGREEMENT

          THIS RESTRICTED STOCK PURCHASE AGREEMENT (this "Agreement") is dated
as of the ___ day of __________, _____, by and between Esperion Therapeutics,
Inc., a Delaware corporation (the "Corporation"), and __________________________
                                   -----------
 ("Purchaser").
   ---------

          SECTION 1.  Definitions.
                      -----------

          As used in this Agreement, the following terms shall have the
following respective  meanings:

          "Persons" shall mean and include a natural person, a corporation, a
           -------
limited liability company, a partnership, a trust, an unincorporated
organization and a government or any department, agency or political subdivision
thereof.

          "Securities Act" shall mean the Securities Act of 1933, as amended,
           --------------
and any successor statute and the rules and regulations of the Securities and
Exchange Commission thereunder, as shall be in effect as the applicable time.

          "Shares" shall mean the shares of Common Stock purchased by Purchaser
           ------
hereunder.

          "Transfers" shall include any direct or indirect sale, assignment,
           ---------
transfer, pledge (but not including a pledge in favor of the Corporation),
hypothecation or other disposition of any Shares or of any legal or beneficial
interest therein.

          SECTION 2.  Sale to Purchaser of Common Stock. Subject to the terms
                      ---------------------------------
and conditions contained herein, the Corporation hereby sells, transfers and
assigns to Purchaser, and Purchaser hereby purchases from the corporation, the
Shares. The Corporation hereby acknowledges receipt from Purchaser of payment of
the Original Cost Per Share (or US$_____ in the aggregate).

          SECTION 3.  Legend on Shares.
                      ----------------

          3.1.  Restrictive Legends.
                --------------------

                (a)   Each certificate evidencing Shares, and each certificate
evidencing Shares held by subsequent transferees of any such certificate, shall
(unless otherwise permitted by the provisions of Section 3.2 hereof) be stamped
or otherwise imprinted with a legend in substantially the following form:

          THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE
          BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN
          REGISTERED UNDER THE SECURITIES ACT OF 1933, AS
          AMENDED, OR ANY STATE SECURITIES LAW, THESE
<PAGE>

          SECURITIES MAY NOT BE SOLD OR TRANSFERRED IN THE
          ABSENCE OF SUCH REGISTRATION OR ANY EXEMPTION THEREFROM
          UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY
          APPLICABLE STATE SECURITIES LAW.

               (b)   Each certificate evidencing Shares, and each certificate
evidencing Shares held by subsequent transferees of any such certificate, shall
(unless otherwise permitted by the provisions of Section 3.2 hereof) also be
stamped or otherwise imprinted with a legend in substantially the following
form:

          ADDITIONALLY, THE TRANSFER OF THESE SECURITIES IS SUBJECT TO THE TERMS
          AND CONDITIONS OF A RESTRICTED STOCK PURCHASE AGREEMENT DATED AS OF
          ____________________________,  AMONG ESPERION THERAPEUTICS, INC. AND
          THE HOLDER OF RECORD OF THIS CERTIFICATE AND NO SALE, ASSIGNMENT,
          TRANSFER, PLEDGE, HYPOTHECATION OR OTHER DISPOSITION OF SUCH
          SECURITIES SHALL BE VALID OR EFFECTIVE EXCEPT IN ACCORDANCE WITH SUCH
          AGREEMENT AND UNTIL SUCH TERMS AND CONDITIONS HAVE BEEN FULFILLED.
          COPIES OF SUCH AGREEMENT MAY BE OBTAINED AT NO COST BY WRITTEN REQUEST
          MADE BY THE HOLDER OF RECORD OF THIS CERTIFIATE TO THE SECRETARY OF
          ESPERION THERAPEUTICS, INC.

          SECTION 4. Covenants of Purchaser. Purchaser agrees that he or she
                     ----------------------
shall not Transfer any of his or her Shares except as permitted (i) in that
certain Stockholders' Agreement dated as of ______________, by and among the
Corporation, the Purchaser, and the other parties thereto and (ii) in that
certain Investors' Rights Agreement dated as of __________________, by and among
the Corporation and the parties thereto.

          SECTION 5. Representations.
                     ---------------

          5.1. Representations of Purchaser.  In connection with Purchaser's
               ----------------------------
purchase of the Shares, Purchaser hereby represents and warrants to the
Corporation as follows:

               (a)   Investment Intent; Capacity to Protect Interests. Purchaser
                     ------------------------------------------------
is purchasing the Shares solely for his or her own account for investment and
not with a view to or for sale in connection with any distribution of the Shares
or any portion thereof and not with any present intention of selling, offering
to sell or otherwise disposing of or distributing the Shares or any portion
thereof in any transaction other than a transaction exempt from registration
under the Securities Act. Purchaser also represents that the entire legal and
beneficial interest of the Shares is being purchased, and will be held, for his
or her account only, and neither in whole or in part for any other person.

                                       2
<PAGE>

               (b)   Restricted Securities. Purchaser understands and
                     ---------------------
acknowledges that the Shares have not been registered under the Securities Act;
that the Shares must be held indefinitely unless subsequently registered under
the Securities Act or an exemption from such registration is available; and that
the corporation is under no obligation to register the Shares.

               (c)   Disposition under Rule 144. Purchaser understands that the
                     --------------------------
Shares are restricted securities within the meaning of Rule 144 promulgated
under the Securities Act; that the exemption from registration under Rule 144
will not be available in any event for at least two years from the date of
purchase of any payment for the Shares, and even then will not be available
unless (i) a public trading market then exists for the Shares, (ii) adequate
information concerning the Corporation is then available to the public, and
(iii) other terms and conditions of Rule 144 are complied with; and that any
sale of the Shares may be made only in limited amounts in accordance with such
terms and conditions.

          5.2. Representations of the Corporation. The Corporation represents to
               ----------------------------------
Purchaser that:

               (a)   The execution, delivery and performance by the Corporation
of this Agreement and all transactions contemplated by this Agreement have been
duly authorized by all action required by law, its Certificate of Incorporation,
its Bylaws or otherwise.

               (b)   This Agreement has been duly executed and delivered by the
Corporation and constitutes the legal, valid and binding obligation of the
Corporation enforceable against it in accordance with its terms.

          SECTION 6. Withholding.  Upon the request of the Corporation,
                     -----------
Purchaser shall promptly pay to the Corporation, or make arrangements
satisfactory to the Corporation regarding payment of, any Federal, state or
local taxes of any kind required by law to be withheld with respect to the
Shares (or any distributions of other securities or property (including cash)
thereon or issued in replacement thereof).

          SECTION 7. Remedies.  In case any one or more of the covenants and/or
                     --------
agreements set forth in this Agreement shall have been breached by any party
hereto, the party entitled to the benefit of such covenants or agreements may
proceed to protect and enforce its rights either by suit in equity and/or by
action at law, including, but not limited to, (a) an action for damages as a
result of any such breach, (b) an action for specific performance of any such
covenant or agreement contained in this Agreement, and/or (c) a temporary or
permanent injunction, in any case without showing any actual damage.  The
rights, power and remedies of  the parties under this Agreement are cumulative
and not exclusive of any other agreement or law.  No single or partial assertion
or exercise of any right, power or remedy of a party hereunder shall preclude
any other or further assertion or exercise thereof.  Any purported Transfer in
violation of the provisions of this Agreement shall be null and void ab initio.
                                                                     -- ------

          SECTION 8. Successors and Assigns. Except as otherwise expressly
                     ----------------------
provided herein, this Agreement shall bind and inure to the benefit of the
Corporation, Purchaser, the

                                       3
<PAGE>

respective successors or heirs, distributees and personal representatives and
permitted assigns of the Corporation and Purchaser, and each other person who
shall properly become a registered holder of any Shares that have not
theretofore been sold to the public pursuant to a registration statement under
the Securities Act or Rule 144 or Rule 144A (or any similar or successor rule).

          SECTION 9.  Entire Agreement. This Agreement contains the entire
                      ----------------
agreement among the parties with respect to the subject matter hereof and
supersedes other prior and contemporaneous arrangements or understandings with
respect thereto.

          SECTION 10. Notices. All notices, consents and other communications
                      -------
under this Agreement shall be in writing and shall be deemed to have been duly
given (a) when delivered by hand, (b) one (1) business day after the business
day of transmission, if sent by telex or telecopier (with receipt confirmed),
provided that a copy is mailed by registered mail, return receipt requested, or
--------
(c) one (1) business day after the business day of deposit with the carrier, if
sent by Express Mail, Federal Express or other express delivery service (receipt
requested), in each case to the appropriate addresses, telex numbers and
telecopier numbers set forth below (or to such other addresses or telecopy
numbers as a party may designate as to itself by notice to the other parties):

          (a)  If to Purchaser:

          (b)  If to Corporation:

                    Esperion Therapeutics, Inc.
                    3621 S. State Street, 695 KMS Place
                    Ann Arbor, Michigan 48108
                    Telecopier No.: (734) 332-0516
                    Attention:  Roger Newton, Ph.D.

               With a copy to:

                    Sills Cummis Zuckerman Radin
                    Tischman Epstein & Gross, P.A.
                    One Riverfront Plaza
                    Newark, New Jersey 07101
                    Telecopier No.: (973) 643-6500
                    Attention: Ira A. Rosenberg, Esq.

                                       4
<PAGE>

          SECTION 11.  Changes.  The terms and provisions of this Agreement may
                       -------
not be modified or amended, or any of the provisions hereof waived, temporarily
or permanently, without the prior written consent of each of the parties hereto.

          SECTION 12.  Counterparts. This Agreement may be executed in any
                       ------------
number of counterparts, and each such counterpart shall be deemed to be an
original instrument, but all such counterparts together shall constitute but one
agreement.

          SECTION 13.  Headings. The benefits of the various sections of this
                       --------
Agreement have been inserted for convenience of reference only and shall not be
deemed to be part of this Agreement.

          SECTION 14.  Nouns and Pronouns. Whenever the context may require, any
                       ------------------
pronouns used herein shall include the corresponding masculine feminine or
neuter forms, and the singular form of names and pronouns shall include the
plural and vice-versa.

          SECTION 15.  Severability. Any provision of this Agreement that is
                       ------------
prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction,
be ineffective to the extent of such prohibition or unenforceability. Such
prohibition or unenforceability in any one jurisdiction shall not invalidate or
render unenforceable such provision in any other jurisdiction.

          SECTION 16.  Governing Law. This Agreement and (unless otherwise
                       -------------
provided) all amendments hereof and waivers and consents hereunder shall be
governed by the internal law of the State of Delaware, without regard to the
conflicts of law principles thereof.

          IN WITNESS WHEREOF, the parties hereto have executed this Agreement as
of the date and your first written above.

                                             ESPERION THERAPEUTICS, INC.

                                             By:___________________________
                                             Name:
                                             Title:

                                             ______________________________

                                             By:___________________________
                                             Name:
                                             Title:

                                       5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00012-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00012-of-00352.parquet"}]]